ClinicalTrials.Veeva

Menu
O

Oregon Medical Research Center | Portland, OR

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
Upadacitinib
Guselkumab
Rocatinlimab
Ixekizumab
Lebrikizumab
Dupilumab
Risankizumab
PF-04965842
A-101

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 66 total trials

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants...

Active, not recruiting
Myelodysplastic Syndromes (MDS)
Drug: Azacitidine
Drug: Venetoclax

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the...

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Placebo

The objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric participants...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib (ABT-494)

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle g...

Enrolling
Seborrheic Keratosis
Drug: SM-020 gel 1.0%
Drug: Vehicle gel

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescen...

Active, not recruiting
Alopecia Areata
Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
Locations recently updated

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people expe...

Active, not recruiting
Spinal Cord Injury (SCI)
Drug: Placebo
Drug: Elezanumab

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will asse...

Enrolling
Scalp Psoriasis
Genital Psoriasis
Drug: Risankizumab
Drug: Placebo for Risankizumab

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CH...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

Trial sponsors

Lilly logo
AbbVie logo
Amgen logo
Pfizer logo
Incyte logo
Janssen (J&J Innovative Medicine) logo
Aclaris Therapeutics logo
Allergan logo
Galderma logo
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems